BioCardia (BCDA) Expected to Announce Quarterly Earnings on Wednesday

BioCardia (NASDAQ:BCDA – Get Free Report) is expected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect BioCardia to post earnings of ($0.15) per share for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. On average, analysts expect BioCardia to post ($0.71) EPS for the current fiscal year and ($0.58) EPS for the next fiscal year.

BioCardia Stock Performance

NASDAQ:BCDA opened at $0.90 on Tuesday. BioCardia has a fifty-two week low of $0.75 and a fifty-two week high of $1.80. The firm has a market cap of $13.67 million, a PE ratio of -1.41 and a beta of 0.69. The business has a 50 day moving average price of $1.02 and a 200-day moving average price of $1.07.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. HC Wainwright reissued a “buy” rating on shares of BioCardia in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a report on Thursday, October 15th. Finally, Zacks Research upgraded shares of BioCardia from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.00.

View Our Latest Report on BioCardia

BioCardia Company Profile

(Get Free Report)

BioCardia, Inc is a biotechnology company focused on developing regenerative cell therapies and delivery systems for the treatment of cardiovascular diseases. The company’s programs are designed to address conditions in which damaged or poorly functioning heart tissue may benefit from cellular therapy.

BioCardia’s principal product candidates include CardiAMP Cell Therapy, an autologous treatment that uses a patient’s own bone marrow-derived cells, and CardiALLO Cell Therapy, an investigational allogeneic therapy based on mesenchymal precursor cells from a donor source.

Further Reading

Earnings History for BioCardia (NASDAQ:BCDA)

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.